TetraLogic Pharmaceuticals Company Description
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases.
It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells.
SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma.
TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease.
The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006.
TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
| Country | United States |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
Contact Details
Address: 343 Phoenixville Pike Malvern, Delaware 19355 United States | |
| Phone | 610 889 9900 |
| Website | tetralogicpharma.com |
Stock Details
| Ticker Symbol | TLOG |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US88165U1097 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yigong Shi Ph.D. | Co-Founder |